According to the NASDAQ site, 2 seconds before the market close (4:00p), a transaction for 180 shares went off @ $3.1041. At approximately 4:03 (37 sec), the next transaction took place for 404 shares @ $.3.34. The last transaction shown on the NASDAQ site was for 118 shares @ $3.37.
Al proceeds from the sale go to the seller, not FRSH. The sale, however, alleviates the overhang of marketable shares, which should propel the price of FRSH stock higher in the near future.
You will soon see what Baxter and Baxalta will be trading for on June 15. On that date the two stocks will be trading on a "when issued" basis (wi). Management is likely prohibited from commenting on the price movements of its stock during a pending breakup of its company into two separate companies. I believe the price decline in Baxter stock is related to the pending spinoff and how investors perceive how their investment in Baxter will be effected.
Go to Baxter Corp homepage. Click on icon on right labeled "Creating Two Independent Companies." When the page comes up, scroll down the page to "Transition Updates", and click on "June 5, 2015 Amendment No. 5" to Form 10." The resulting SEC document is 218 pages and provides all the info you need to understand the spinoff of Baxalta by Baxter Corp. I suggest you all skim through it as it's very informative. I hope this helps clarify your concerns.
The startup Fitbit has filed for an IPO that will raise at least $100 million. Some claim it could raise as much as $400 million. Fitbit has already racked up $1.2 billion in revenue and is profitable, according to sources. Fitbit makes fitness wearables. There must be quite a sizeable market for these things.
I'm not aware of any connection, although BAX has collaborative arrangements with Coherus Pharma and Momenta pharma, both involved in biosimilar drugs like EPRS.
The more negativity, the better. After a while, all this negativity will be self-defeating. When analysts throw everything they have at a stock and can't drive it down, the stock will usually start its upward trend. Maybe that's what's happening now.
That is not the reason. Many stocks are not participating in this rally. ZU is going up for reasons I previously spelled out in other messages. In my opinion, one of the causes for the stock's strength the last two days is the fact that ZU has been beaten down to a doomsday scenario. The latest quarterly report just added to the overwhelming negativity on this stock. Yes, the company has been derailed momentarily, but it will get back on track.
After a company's stock price has a tremendous drop in its price like ZU has experienced, analysts usually downgrade the stock. They falsely believe that it makes them look like they were negative on the stock all along. Investors rarely look at the date they made their downgrade and compare it to the company' stock price, say over a 6-month period following the downgrade.. Why would you want to short ZU when last year the stock was at $75 a share?. Don't you think a lot of negative news is already reflected in ZU? The company has plenty of cash and is hovering around the break-even point in earnings. ZU has been a public company only about 18 months. There will be ups and downs for the company during this period until it finds its footing. Patience is a virtue, so don't be impatient like Stifel, which just apologized for having upgraded ZU not too long ago. Stay long if you own ZU and buy for the long-term. I am keeping my ZU shares because everyone is down on the stock--the perfect contrarian indicator. So my friend, learn to march to the beat of a different drummer and don't listen to the crowd mentality.
Why would the shorts cover right after a disastrous quarterly report and below- consensus financial projections for the current quarter and the full year? The shorts will start covering when ZU starts on an upward trend.
ZU is moving higher because the company: (1) is improving its delivery time for products; (2) has improved its website; (3) has hired a new CFO; (4) is more aware of what actions need to be taken to improve its performance; and (5) has instituted a stock buyback program which will support its stock price.
I hope it all works out well, as investors have suffered much pain to date.
I previously bought WFM in late October of last year @ $39, right before its quarterly earnings report, and sold my holdings in late February and early March of this year @ around $53-$54. Looking at a one-year chart, it seems WFM is retracing its big upward move during this time back to the $39-$40 area.. I'm not a chartist, but it looks like a potential buying point if it reaches that level. For those of you who know technical charting, I'd appreciate what your thoughts are, as I'd like to jump back in and buy WFM. Thanks!
Zulily has about $370 million of cash on hand. After they beat those low-ball 2Q revenue estimates and their stock moves up, it wouldn't surprise me if Zulily acquires somebody. Maybe another internet retailer or somebody in the retail technology area.
ZU is not a very well managed company and there may well be more pain to come. However, there is an opportunity to turn the company around and start showing some growth in the company's financial metrics. Selling stuff on the internet is not rocket science, although some companies like ZU make it more difficult than it really is. I'm sure someone in the company will eventually figure out what it takes to get the company on track. About 14 months ago, the stock closed the day at nearly $75 a share, so looking at today's stock price should lead one to believe that ZU is near its last breath. Going from $75 to under $10 in14 months is a serious amount of market cap down the drain. I don't think it's completely warranted. The company deserves to be punished, but not that much. After all, according to Yahoo Finance statistics, the company still has over $1 billion in annual sales, $374 million in cash, no meaningful debt, and is hovering around the breakeven point in earnings. Also, ,the company has stated that it will institute a stock buyback program. Moreover, I would not be surprised if the company's earnings/revenues forecast is very conservative on the low end to enable the company to exceed its forecast and maybe even beat it handily. We will just have to wait and see where the company goes from here. I intend to take a wait-and-see approach.
According to Yahoo Finance, the company has about $85 million of debt, but only $495 thousand in cash. This recall will really hurt, especially coming on the heels of a previous recall. It will be interesting to see how management spins the latest recall during its upcoming conference call on quarterly earnings. As for me, I bailed out of my 13-month investment because I'm not sure what's going to happen to this company. I've been in the red on my investment from day one. Enough is enough. I thought food companies were safe investments. This company proved me wrong.
Hire an investor relations' firm. Issue press releases on breakthroughs to addressing melanoma, brain cancer and ovarian cancer without any clinical trials. The public takes the bait. Stock skyrockets. The outcome is a private stock and rights offering and who knows what else to come.. The biotech investment field is one big game and one that can be very rewarding if you know when to get in and know when to get out.